9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 90 of the 94 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the latest American Diabetes Association (ADA) [62], Italian Society of Diabetology (SID) [63] and KDIGO guidelines [64] differentiate the pharmacological approach to T2DM not just based on the target glycaemic values but also taking into account the indicators of high-risk or established atherosclerotic cardiovascular disease, CKD and heart failure.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [62]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“temshasbeensupported in the literature in adolescents and adults with type 1 diabetes (16,17), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (…”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Research works printed but not linked: 3
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
Cited by
Items 201–300 of 975
Yang, Y., Miao, C., Wang, Y., He, J., & Bo, Y. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3830 · Cited by 31
“17”
Continuous glucose monitoring in persons with type 2 diabetes not using insulin
Cowart, K., Updike, W. H., & Franks, R. (2021) · Expert Review of Medical Devices · doi:10.1080/17434440.2021.1992274 · Cited by 27
Hwang, J. G., Lee, S., Huh, W., Han, J., Oh, J., Jang, I., & Yu, K. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15348 · Cited by 29
Li, X., Song, Y., Guo, T., Xiao, G., & Li, Q. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101366 · Cited by 33
Mehta, R., Goldenberg, R., Katselnik, D., & Kuritzky, L. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1925148 · Cited by 29
Varshney, N., Billups, S. J., Saseen, J. J., & Fixen, C. W. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098621997703 · Cited by 31
Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus
Kim, J., & Kwon, H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0377 · Cited by 33
Janić, M., Rizzo, M., Cosentino, F., Stoian, A. P., Lunder, M., Šabović, M., & Janež, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01226-y · Cited by 28
Xu, Z., Yang, S., & Cui, L. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03808-3 · Cited by 32
“In the “2021 Standards of Medical Care in Diabetes,” the American Diabetes Association (ADA) recommends considering glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in addition to SGLT2i for patients with high risk or established CKD [199].”
BackgroundManaging dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 33
Yagi, N., Komiya, I., Arai, K., Oishi, M., Fukumoto, Y., Shirabe, S., Yokoyama, H., Yamazaki, K., Sugimoto, H., & Maegawa, H. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13621 · Cited by 28
Fang, H. S. A., Gao, Q., Tan, W. Y., Lee, M. L., Hsu, W., & Tan, N. C. (2022) · BMC Medicine · doi:10.1186/s12916-021-02221-z · Cited by 33
Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines
Mohan, V., Saboo, B., Khader, J., Modi, K. D., Jindal, S., WANGNOO, S. K., & Sugumaran, A. (2022) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514221074663 · Cited by 35
Chan, G. C., Ng, J. K., Chow, K. M., & Szeto, C. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110200 · Cited by 29
Gravel, C. A., Krewski, D. R., Mattison, D. R., Momoli, F., & Douros, A. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15711 · Cited by 26
Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease
Adem, M. A., Decourt, B., & Sabbagh, M. N. (2024) · Biomedicines · doi:10.3390/biomedicines12010099 · Cited by 34
“Metformin, a biguanide derivative, is an insulin-sensitizing agent and the current first-line antidiabetic on the market [37].”
BackgroundmTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy
Saha, S., Fang, X., Green, C. D., & Das, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015078 · Cited by 26
“In T2D, metformin is usually the first-line standard treatment [87] and though a few studies have shown metformin to exert cardioprotective effects via mTORC1 regulation [57], these reports are very limited despite a long history of metformin use [88].”
BackgroundMetformin-Associated Gastrointestinal Adverse Events Are Reduced by Probiotics: A Meta-Analysis
Szymczak-Pajor, I., Drzewoski, J., Wenclewska, S., & Śliwińska, A. (2024) · Pharmaceuticals · doi:10.3390/ph17070898 · Cited by 30
“In increasing the initial dosage of the drug may contribute practice, to minimize the GI adverse events, a decrease in the dose of metformin or ceasing it should be considered [28].”
BackgroundMohan, V., Zargar, A. H., Chawla, M. S., Joshi, A. S., Ayyagari, U., Sethi, B. K., Gaurav, K., Patted, U. R. H., Bhagat, S. V., & Mane, A. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s315227 · Cited by 25
Moazzeni, S. S., Arani, R. H., Deravi, N., Hasheminia, M., Khalili, D., Azizi, F., & Hadaegh, F. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01326-2 · Cited by 26
Orabi, D., Berger, N. A., & Brown, J. M. (2021) · Cancers · doi:10.3390/cancers13143473 · Cited by 28
Schechter, M., Cohen, C. M., Rozenberg, A., Yanuv, I., Chodick, G., Karasik, A., Kosiborod, M., & Mosenzon, O. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01362-y · Cited by 26
Type 2 Diabetes Remission with Significant Weight Loss: Definition and Evidence-Based Interventions
Ko, J. H., & Kim, T. N. (2022) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22001 · Cited by 31
Alguwaihes, A. M., Alhozali, A. M., Yahia, M., Abdel-Nabi, T., Hatahet, M. H., Albalkhi, N., & Sifri, S. A. (2023) · Saudi Medical Journal · doi:10.15537/smj.2023.44.1.20220402 · Cited by 28
Lau, D., Pannu, N., Yeung, R. O., Scott‐Douglas, N., & Klarenbach, S. W. (2023) · CMAJ Open · doi:10.9778/cmajo.20210281 · Cited by 24
Yabe, D., Deenadayalan, S., Horio, H., Kaneto, H., Jensen, T. B., Terauchi, Y., Yamada, Y., & Inagaki, N. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13764 · Cited by 23
Tang, H., Donahoo, W. T., Svensson, M., Shaaban, C. E., Smith, G. E., Jaffee, M. S., Huang, Y., Hu, X., Lu, Y., Salloum, R. G., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14048 · Cited by 26
“Sulfonylureas were chosen as the active comparator because (1) they were prescribed at a similar disease stage of T2D as SGLT2 inhibitors, 24 which could help reduce the potential confounding by indication/severity, 25,26 and (2) they were not associated with cognitive outcomes and risk of dementia…”
Sipos, Á., Szennyes, E., Hajnal, N. É., Kun, S., Szabó, K. E., Uray, K., Somsák, L., Docsa, T., & Bokor, É. (2021) · Pharmaceuticals · doi:10.3390/ph14040364 · Cited by 25
Shi, F., Li, H., Shen, L., Fu, J., Ma, J., Gu, Z., & Lin, H. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14452 · Cited by 27
Diabetic kidney disease in children and adolescents: an update
Lopez, L. N., Wang, W., Loomba, L. A., Afkarian, M., & Butani, L. (2021) · Pediatric Nephrology · doi:10.1007/s00467-021-05347-7 · Cited by 31
Bala, C. G., Cerghizan, A., Mihai, B. M., Moise, M., & Guja, C. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-060852 · Cited by 26
Zhan, J., Jin, K., Ding, N., Zhou, Y., Guo, H., Yuan, S., Xie, R., Zheng, W., Chen, C., Li, H., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.12.009 · Cited by 24
Jung, H., Tittel, S. R., Schloot, N. C., Heitmann, E., Otto, T., Lebrec, J., Pavel, M., & Lanzinger, S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15038 · Cited by 25
Zhao, Q., Yang, J., Li, J., Zhang, L., Yan, X., Yue, T., & Yuan, Y. (2023) · Food Research International · doi:10.1016/j.foodres.2023.113689 · Cited by 25
Klein, K. R., Clemmensen, K. K. B., Fong, E., Olsen, S., Abrahamsen, T., & Lingvay, I. (2024) · Diabetes Care · doi:10.2337/dc23-1791 · Cited by 22
Trends in U.S. Insulin Use and Glucose Monitoring for People with Diabetes: 2009-2018
Perez-Nieves, M., Juneja, R., Fan, L., Meadows, E., Lage, M. J., & Eby, E. L. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211028268 · Cited by 22
Shrestha, D. B., Budhathoki, P., Sedhai, Y. R., Karki, P., Gurung, S., Raut, S. R., Damonte, J. I., Buono, M. G. D., Mojadidi, M. K., Elgendy, I. Y., et al. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001099 · Cited by 26
Hawley, C. E., Lauffenburger, J. C., Paik, J. M., Wexler, D. J., Kim, S. C., & Patorno, E. (2022) · Diabetes Care · doi:10.2337/dc21-1676 · Cited by 22
Di Loreto, C., Minarelli, V., Nasini, G., Norgiolini, R., & Del Sindaco, P. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01218-y · Cited by 21
Euh, W., Lim, S. K., & Kim, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.613389 · Cited by 25
Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence
Roy, A., Sahoo, J., Narayanan, N., Merugu, C., Kamalanathan, S., & Naik, D. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i9.1426 · Cited by 24
Cefalu, W. T., Andersen, D. K., Arreaza-Rubín, G., Pin, C. L., Sato, S. M., Verchere, C. B., Woo, M., & Rosenblum, N. D. (2021) · Diabetes · doi:10.2337/db21-0777 · Cited by 22
Scheen, A. J., & Delanaye, P. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101315 · Cited by 24
Górriz, J. L., Romera, I., Cobo, A., O’Brien, P. D., & Merino-Torres, J. F. (2022) · Diabetes Therapy · doi:10.1007/s13300-021-01198-5 · Cited by 32
Neeland, I. J., Al-Kindi, S. G., Tashtish, N., Eaton, E., Friswold, J., Rahmani, S., Solaru, K. W., Rashid, I., Berg, D., Rana, M. N., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.120.024482 · Cited by 23
Managing thrombotic risk in patients with diabetes
Camm, A. J., Sabbour, H. M., Schnell, O., Summaria, F., & Verma, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01581-x · Cited by 28
Neuroendocrine Tumors: A Comprehensive Review on Nutritional Approaches
Muscogiuri, G., Barrea, L., Cantone, M. C., Guarnotta, V., Mazzilli, R., Verde, L., Vetrani, C., Colao, A. A. L., & Faggiano, A. (2022) · Cancers · doi:10.3390/cancers14184402 · Cited by 23
Park, C. S., Choi, E., Kyung-DoHan, Yoo, J., Ahn, H., Kwon, S., Lee, S., Oh, S., & Lip, G. Y. H. (2022) · Diabetes Care · doi:10.2337/dc22-1655 · Cited by 21
Ng, N. M., Ng, Y. S., Chu, T. K., & Lau, P. M.-Y. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01928-z · Cited by 27
Jain, V., Qamar, A., Matsushita, K., Vaduganathan, M., Ashley, K. E., Khan, M. S., Bhatt, D. L., Arora, S., & Caughey, M. C. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028923 · Cited by 21
Martínez-Solís, J., Calzada, F., Barbosa, E., & Valdés, M. (2021) · Molecules · doi:10.3390/molecules26092408 · Cited by 25
Colling, C., Atlas, S. J., & Wexler, D. J. (2021) · Diabetes Care · doi:10.2337/dc21-0013 · Cited by 26
Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus
Lee, J., Kim, R., Kim, M.-H., Lee, S.-H., Cho, J.-H., Lee, J. M., Jang, S.-A., & Kim, H.-S. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.07.006 · Cited by 20
Maranta, F., Cianfanelli, L., Rizzo, M., & Cianflone, D. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.12.074 · Cited by 20
Dichtel, L. E. (2021) · Hepatology · doi:10.1002/hep.31886 · Cited by 26
Xu, D., Chandler, O., Wee, C., Ho, C. L. B., Affandi, J. S., Yang, D.-Y. D., Liao, X., Chen, W., Li, Y., Reid, C. M., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.712671 · Cited by 22
HbA1c-Triggered Endocrinology Electronic Consultation for Type 2 Diabetes Management
Oseran, A. S., Rao, K., Chang, Y., He, W. W., Sikora, C., Wexler, D. J., & Horn, D. M. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07157-x · Cited by 22
Han, Y., Cheng, B., Guo, Y., Wang, Q., Yang, N., & Lin, P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.779636 · Cited by 24
González‐González, J. G., Solís, R. C., González-Colmenero, A. D., Raygoza-Cortez, K., Moreno-Peña, P. J., Sánchez, A. L., McCoy, R. G., Ospina, N. S., Maraka, S., Brito, J. P., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109821 · Cited by 24
Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?
Blüher, M., Ceriello, A., Davies, M., Rodbard, H., Sattar, N., Schnell, O., Tonchevska, E., & Giorgino, F. (2022) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.330 · Cited by 20
SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review
Kansara, A., Mubeen, F., & Shakil, J. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1120 · Cited by 25
Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel
Lyu, B., Sang, Y., Selvin, E., Chang, A. R., Alexander, G. C., Cohen, C. M., Coresh, J., Shalev, V., Chodick, G., Karasik, A., et al. (2022) · Diabetes Care · doi:10.2337/dc22-1253 · Cited by 21
Li, J. H., Perry, J. A., Jablonski, K. A., Srinivasan, S., Chen, L., Todd, J. N., Harden, M. V., Mercader, J. M., Pan, Q., Dawed, A. Y., et al. (2023) · Diabetes · doi:10.2337/db22-0702 · Cited by 22
Zhang, X., & Marx, C. M. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.3.276 · Cited by 24
Luo, J., Feldman, R., Rothenberger, S., Korytkowski, M., Fischer, M. A., & Gellad, W. F. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07331-1 · Cited by 18
Kietaibl, A.-T., Fasching, P., Glaser, K. S., & Petter‐Puchner, A. H. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.828649 · Cited by 21
Janić, M., Cankar, M., Šmid, J., Štiglic, A. F., Jerin, A., Šabović, M., Janež, A., & Lunder, M. (2022) · Journal of Diabetes Research · doi:10.1155/2022/6796470 · Cited by 25
Tiwari, K., Bisht, M., Kant, R., & Handu, S. S. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_458_22 · Cited by 19
Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes
Alduraibi, R. K., Alrebdi, Y. M., & Altowayan, Y. F. (2023) · Medicine · doi:10.1097/md.0000000000034027 · Cited by 21
Kim, N. Y., Lee, H., Kim, S. H., Kim, Y., Lee, H., Lee, J., Kwak, S. H., & Lee, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-55313-0 · Cited by 27
“According to ADA guidelines, we defined prediabetes as either a fasting glucose level of 100–125 mg/dL, a 2-h glucose level ranging from 140 mg/dL to 199 mg/dL during the 75-g oral glucose tolerance test, or an elevated HbA1c level ranging from 5.7% to 6.4% (39 to 46 mmol/mol) 23 .”
InfluentialCamilli, M., Viscovo, M., Maggio, L., Bonanni, A., Torre, I., Pellegrino, C., Lamendola, P., Tinti, L., Teofili, L., Hohaus, S., et al. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01059-9 · Cited by 22
“The ramifications of SGLT2 inhibition in lipid metabolism also enable to understand their atheroprotective effect [8, 133].”
Scheen, A. J., & Delanaye, P. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2014322 · Cited by 21
Yang, C., Peng, Z., Chen, Y.-C., Ou, H., & Kuo, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.836365 · Cited by 22
Examining the evidence for weight management in individuals with type 2 diabetes
Garvey, W. T., Umpierrez, G. E., Dunn, J. P., Kwan, A. Y. M., Varnado, O. J., Konig, M., & Levine, J. A. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14764 · Cited by 18
Predicting responsiveness to GLP-1 pathway drugs using real-world data
Zhu, X., Fowler, M. J., Wells, Q. S., Stafford, J. M., & GANNON, M. A. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01798-9 · Cited by 22
“When cost is not an issue, the ADA recommends choosing a second-line medication from one of the following: dipeptidyl peptidase-4 inhibitors (DPP4i), glucagon-like peptide-1 receptor agonists (GLP-1-RA), or sodium/glucose co-transporter inhibitors (SGLT2i) [3].”
InfluentialDegradation of insulin amyloid by antibiotic minocycline and formation of toxic intermediates
Mori, W., Yuzu, K., Lobsiger, N., Nishioka, H., Sato, H., Nagase, T., Iwaya, K., Lindgren, M., & Zako, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-86001-y · Cited by 20
Lalagkas, P. N., Poulentzas, G., Kontogiorgis, C. A., & Douros, A. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1921735 · Cited by 19
Ang, L. P., Kidwell, K., Dillon, B. R., Reiss, J., Fang, F., LEONE, V. A., Mizokami‐Stout, K., & Pop‐Busui, R. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107949 · Cited by 19
Incretin based therapy and pancreatic cancer: Realising the reality
Suryadevara, V., Roy, A., Sahoo, J., Kamalanathan, S., Naik, D., Mohan, P., & Kalayarasan, R. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i25.2881 · Cited by 23
The Impact of Using Carbohydrate Counting on Managing Diabetic Patients: A Review
Ibrahim, S. M. H., Shahat, E. A., Amer, L. A., & Aljohani, A. K. (2023) · Cureus · doi:10.7759/cureus.48998 · Cited by 30
“Educating patients on how to modify prandial insulin dosing based on carbohydrate intake, preprandial glucose levels, and anticipated exercise can be highly beneficial and is advised for the majority of patients [17].”
BackgroundAlkabbani, W., & Gamble, J. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s281602 · Cited by 19
Simplification of complex insulin therapy: a story of dogma and therapeutic resignation
Giugliano, D., Scappaticcio, L., Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., & Esposito, K. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108958 · Cited by 22
Liao, P.-Y., Lo, H., Liu, I.-C., Lo, L.-C., Hsiang, C., & Ho, T. (2022) · Food & Function · doi:10.1039/d1fo02788c · Cited by 19
Igarashi, A., Maruyama-Sakurai, K., Kubota, A., Akiyama, H., Yajima, T., Kohsaka, S., & Miyata, H. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01270-8 · Cited by 17
Remchak, M. E., Piersol, K. L., Bhatti, S., Spaeth, A. M., Buckman, J. F., & Malin, S. K. (2021) · Nutrients · doi:10.3390/nu13051708 · Cited by 21
Napoli, R., Avogaro, A., Formoso, G., Piro, S., Purrello, F., Targher, G., & Consoli, A. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.039 · Cited by 18
Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review
Popovic, D. S., Παπάνας, Ν., Stoian, A. P., Rizvi, A. A., Janež, A., & Rizzo, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01170-3 · Cited by 18
Liu, Z., Wang, C., Yang, D., Luo, S., Ding, Y., Xu, W., Zheng, X., Weng, J., & Yan, J. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13870 · Cited by 20
Chadha, M. D., Jain, S. M., Chawla, R., Dharmalingam, M., Chaudhury, T., Talwalkar, P., Tripathi, S., Singh, S., Gutch, M., & Dasgupta, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230116150205 · Cited by 22
“The addition of premix insulin (twice daily) is suggested if glycated hemoglobulin levels remain high despite adding prandial insulin [38].”
BackgroundInfluentialChoi, J., Lee, S., Choi, E., Lee, H.-J., Han, M., Ahn, H., Kwon, S., Lee, S., Han, K., Oh, S., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01736-4 · Cited by 20
Yi, Y., Kwon, E., Yun, G., Park, S., Jeong, J. C., Na, K. Y., Chin, H. J., Yoo, S., Kim, S., Oh, T. J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-52078-4 · Cited by 25
Hlyan, N. P., Arif, T., Jaufar, S. S., Rehman, A., Ayalew, B. D., Batu, B. J., Hundesa, M. I., Hlaing, M. S., Islam, H., Islam, R., et al. (2024) · Cureus · doi:10.7759/cureus.57241 · Cited by 25
“Other oral medications, injectable therapies like GLP-1 agonists, or insulin are added as needed to achieve glycemic targets [13].”
New insights into the roles of Irisin in diabetic cardiomyopathy and vascular diseases
Zhang, T., Qian, Y., Huang, W., Feng, J., & Liu, H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116631 · Cited by 25
Galis, P., Bartosova, L., Farkašová, V., Barteková, M., Ferenczyová, K., & Rajtík, T. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1451100 · Cited by 21
Hsiao, F., Lin, C., Tung, Y., Chang, P., McMurray, J. J. V., & Chu, P. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.02.035 · Cited by 19
Canonico, M. E., Hsia, J. A., Guthrie, N. L., Simmons, M. L., Mehta, P., Lupinacci, P. J., Edwards, K. G., Mosesso, K., Gearhart, M., Skuban, A., et al. (2022) · Clinical Cardiology · doi:10.1002/clc.23853 · Cited by 21
Hu, X., Deng, H., Zhang, Y., Guo, X., Cai, M., Ling, C., & Li, K. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s297913 · Cited by 15
Kim, H. S., Yoon, T., Jung, C. H., Park, J., & Lee, W. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0232 · Cited by 18
Al-Shamasi, A.-A., Elkaffash, R., Mohamed, M., Rayan, M., Al-Khater, D., Gadeau, A., Ahmed, R., Hasan, A., Eldassouki, H., Yalcin, H. C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312677 · Cited by 19
Kim, C. H., Hwang, I.-C., Choi, H.-M., Ahn, C. H., Yoon, Y. E., & Cho, G.-Y. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.06.027 · Cited by 16
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S111-S124
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4254445254
- Cited by
- 972
- References
- 94
- Citations by year
- 2026: 29 · 2025: 55 · 2024: 86 · 2023: 148 · 2022: 334 · 2021: 318 · 2020: 1
- FWCI
- 30.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- pharmacotherapy, diabetes management, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.